This story has been updated to include additional information from a US survey on people's attitudes about cost of genetic testing. Originally published June 4.

CHICAGO – When presented with hypothetical scenarios under which they could receive pharmacogenetic testing to gauge whether they were likely to respond to chemotherapy or experience toxicities to treatment, the majority of cancer patients involved in a Canadian study wanted the diagnostic evaluations and were willing to make an out-of-pocket investment to learn the results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.